We are live on
!
Find out more
PC
Polar Capital Portfolio holdings
AUM
$13.5B
1-Year Est. Return
55.9%
This Fund
S&P 500
This Quarter
Est. Return
+34.87%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$11.6B
AUM Growth
+$2.27B
(+24%)
Cap. Flow
-$278M
Cap. Flow
% of AUM
-2.4%
Top 10 Holdings %
Top 10 Hldgs %
30.23%
Holding
354
New
65
Increased
75
Reduced
125
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$106M |
| 2 |
Meta Platforms (Facebook)
META
|
+$106M |
| 3 |
PayPal
PYPL
|
+$105M |
| 4 |
XLNX
Xilinx Inc
XLNX
|
+$99.5M |
| 5 |
Ciena
CIEN
|
+$86.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$85.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$84.6M |
| 3 |
Amazon
AMZN
|
+$72.7M |
| 4 |
Intel
INTC
|
+$72.2M |
| 5 |
RingCentral
RNG
|
+$71.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.14% |
| 2 | Healthcare | 19.11% |
| 3 | Financials | 17.15% |
| 4 | Communication Services | 12.94% |
| 5 | Consumer Discretionary | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVRO
251
DELISTED
NEVRO CORP.
NVRO
| $292K | ﹤0.01% |
+2,444
| New | +$290K |
|
252
Assembly Biosciences
ASMB
$516M
| $291K | ﹤0.01% |
+1,041
| New | +$243K |
|
253
Penumbra
PEN
$12.6B
| $281K | ﹤0.01% |
1,569
| – | – |
|
254
Veracyte
VCYT
$4.77B
| $275K | ﹤0.01% |
+10,611
| New | +$264K |
|
|
VIVO
255
DELISTED
Meridian Bioscience Inc
VIVO
| $275K | ﹤0.01% |
+11,798
| New | +$171K |
|
|
LHCG
256
DELISTED
LHC Group LLC
LHCG
| $257K | ﹤0.01% |
1,473
-2,285
| -61% | -$335K |
|
257
AdaptHealth
AHCO
$1.45B
| $247K | ﹤0.01% |
15,331
-70,487
| -82% | -$1.18M |
|
258
iRhythm Holdings
IRTC
$3.91B
| $230K | ﹤0.01% |
+1,982
| New | +$219K |
|
|
CNST
259
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $216K | ﹤0.01% |
+7,196
| New | +$259K |
|
|
CHNG
260
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $211K | ﹤0.01% |
+18,866
| New | +$212K |
|
|
SPNE
261
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $208K | ﹤0.01% |
19,901
+5,500
| +38% | +$56.2K |
|
|
ACH
262
Accendra Health
ACH
$256M
| $200K | ﹤0.01% |
+26,250
| New | +$192K |
|
|
FENG
263
Phoenix New Media
FENG
$17.8M
| $185K | ﹤0.01% |
20,837
+3,769
| +22% | +$31.2K |
|
|
XENT
264
DELISTED
Intersect ENT, Inc
XENT
| $183K | ﹤0.01% |
13,485
-947,842
| -99% | -$11M |
|
|
AIMT
265
DELISTED
Aimmune Therapeutics
AIMT
| $170K | ﹤0.01% |
+10,152
| New | +$172K |
|
|
266
AbbVie
ABBV
$455B
| – | – |
-1,123,701
| Closed | -$85.6M |
|
267
Autodesk
ADSK
$49.6B
| – | – |
-40,706
| Closed | -$6.35M |
|
268
Alamos Gold
AGI
$11.9B
| – | – |
-425,915
| Closed | -$2.69M |
|
269
Applied Materials
AMAT
$398B
| – | – |
-1,389,059
| Closed | -$63.6M |
|
270
Arista Networks
ANET
$215B
| – | – |
-5,216,352
| Closed | -$66M |
|
271
Booz Allen Hamilton
BAH
$8.22B
| – | – |
-93,942
| Closed | -$6.45M |
|
272
Biogen
BIIB
$30.7B
| – | – |
-50,000
| Closed | -$15.8M |
|
273
Boston Scientific
BSX
$68.4B
| – | – |
-1,670,649
| Closed | -$54.5M |
|
274
Cigna
CI
$76.1B
| – | – |
-79,074
| Closed | -$14M |
|
|
CMA
275
DELISTED
Comerica
CMA
| – | – |
-81,166
| Closed | -$2.38M |
|
Similar funds
ECM
FAAS
WAM
FS
NIMC
TI
VIM
PS
Polar Capital's Q2 2020 Portfolio in Review
As of Q2 2020, Polar Capital held 354 positions worth $11.6B, up 24% from $9.31B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Polar Capital's Q2 2020 filing shows 65 new, 75 increased, 125 reduced and 74 closed positions. Its largest new stake was TripAdvisor: 3,886,053 shares worth $73.9M. The largest sale was AbbVie, an estimated $85.6M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 36% a quarter earlier, followed by Healthcare and Financials.
- Polar Capital's largest Q2 2020 buy was TripAdvisor: 3,886,053 shares worth $73.9M.
- Polar Capital added most to UnitedHealth in Q2 2020, an estimated $106M increase.
- Polar Capital's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $84.6M.
- Polar Capital fully exited AbbVie in Q2 2020, selling an estimated $85.6M.
- Polar Capital's ten largest holdings make up 30% of its $11.6B portfolio in Q2 2020.
- Polar Capital opened 65 new positions and closed 74 in Q2 2020.
- Polar Capital's portfolio value rose 24% quarter-over-quarter to $11.6B.
Based on Polar Capital's 13F filing for Q2 2020, filed 14 Aug 2020.